Development of Antibody‐Directed Therapies: Quo Vadis?

Less is more: The efficacy of antibody–drug conjugates (ADCs) for cancer therapy is traditionally associated with cleavable linkers for payload release. Evidence now suggests that simpler constructs without cleavable moieties can afford more stable and effective ADCs.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Angewandte Chemie International Edition 2018-02, Vol.57 (8), p.2032-2034
Hauptverfasser:	Rodrigues, Tiago, Bernardes, Gonçalo J. L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals anti-tumor agents antibody–drug conjugates bioconjugation Breast Neoplasms - drug therapy Breast Neoplasms - pathology Bystander Effect Cancer Cell Line, Tumor drug delivery Drug Liberation Female Highlight Highlights Humans Immunoconjugates - chemistry Immunoconjugates - therapeutic use linkers Mice Neoplasms - drug therapy Oligopeptides - chemistry Oligopeptides - metabolism Transplantation, Heterologous
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Less is more: The efficacy of antibody–drug conjugates (ADCs) for cancer therapy is traditionally associated with cleavable linkers for payload release. Evidence now suggests that simpler constructs without cleavable moieties can afford more stable and effective ADCs.
ISSN:	1433-7851 1521-3773
DOI:	10.1002/anie.201712185